Aptose Biosciences Inc. — Investor Relations & Filings

Aptose Biosciences Inc. is a clinical-stage biotechnology company dedicated to developing precision medicines and first-in-class targeted agents for life-threatening cancers, focusing primarily on hematologic malignancies. The company's strategy involves creating differentiated therapies designed for safe single-agent efficacy across multiple indications and enhanced combination potential without overlapping toxicities. Key investigational agents include Tuspetinib, a potent oral Myeloid Kinase Inhibitor (MKI) targeting SYK, FLT3, and JAK, currently in Phase 1/2 for relapsed or refractory Acute Myeloid Leukemia (AML). The pipeline also features Luxeptinib, a dual-acting Kinome Inhibitor. Luxeptinib acts as a Lymphoid Kinome Inhibitor (LKI) in Phase 1a/b trials for B-cell malignancies (CLL/NHL) by non-covalently inhibiting BTK, and as an MKI in Phase 1a/b trials for AML and high-risk Myelodysplastic Syndromes (MDS) by potently inhibiting FLT3.